Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.36) by 11.11 percent. This is a 9.09 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $1.45 million which beat the analyst consensus estimate of $1.05 million by 38.62 percent. This is a 146.02 percent increase over sales of $591.00 thousand the same period last year.